<DOC>
	<DOCNO>NCT02293915</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety Sodium Oligo-mannurarate ( GV-971 ) 36-week treatment mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>An Efficacy Safety Study Sodium Oligo-mannurarate ( GV-971 ) Capsule Treatment Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>1 . Aged 5085 year ( inclusive ) , gender limitation ; 2 . Female subject postmenopausal woman ( menopause &gt; 24 week ) , surgically sterilize woman woman child bear age agree take effective contraceptive measure trial . Women child bear age woman less 24 week menopause must undergo urine pregnancy test screening period result must negative ; 3 . Subjects receive education primary school able complete protocol specify cognitive ability test test ; 4 . Impaired memory least 12 month , tendency progressive aggravation ; 5 . Meet diagnostic criterion probable AD accord National Institute Neurological Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) ( 1984 ) ; 6 . Patients mild moderate disease , i.e . 11 ≤total MMSE score ≤26 ( subject primary school education , 11 ≤total MMSE score ≤22 ) ; 7 . Total Hachinski Ischemia Scale ( HIS ) score ≤4 ; 8 . Total Hamilton Depression Scale/17item ( HAMD ) score ≤10 ; 9 . In screening , cranial MRI plain scan oblique coronal hippocampus scan must perform , subject ≤ 70 age , Fazekas scale white matter lesion ≤grade 1 ( mild white matter lesion ) , subject &gt; 70 age , scale ≤ grade 2 , lacunar infarction lesion diameter large 2 cm ≤2 , without lacunar infarction lesion vital site , thalamus , hippocampus , entorhinal cortex , paraolfactory cortex , cortex subcortical gray matter nucleus ; MRI show high possibility Alzheimer 's disease ( medial temporal lobe atrophy visual rating scale MTA grade ≥2 ) ; 10 . Neurological examination show significant sign ; 11 . Subjects stable , reliable caregiver , least frequent contact caregiver ( least 4 day every week , least 2 h every day ) , caregiver help patient participation study . Caregivers must accompany subject participate study visit sufficient interaction communication subject , provide valuable information NPI , ADCSADL , CIBICplus scale . 12 . Before implementation protocol related procedure examination , subject must sign write informed consent form . If subject sign due limited cognition , legal guardian sign behalf subject meanwhile , legal guardian also sign informed consent form . 1 . Participate another clinical trial within 30 day prior initiation study ; 2 . Pregnant nursing woman ; 3 . Dementia due cause : vascular dementia , central nervous system infection ( e.g . AIDS , syphilis ) , CreutzfeldtJakob disease , Huntington 's chorea , Parkinson 's disease , dementia Lewy body , traumatic dementia , physical chemical factor ( e.g . drug poisoning , alcoholism , carbon monoxide poison ) , significant physical illness ( e.g . hepatic encephalopathy , pulmonary encephalopathy ) , intracranial occupy lesion ( e.g . subdural hematoma , brain tumor ) , endocrine disorder ( e.g . thyroid disease , parathyroid disease ) dementia cause vitamin factor ; 4 . Previous nervous system disorder ( include stroke , optic neuromyelitis , Parkinson 's disease , epilepsy ) ; 5 . Abnormal laboratory value : liver function ( ALT , AST ) &gt; 1.5 time upper limit normal , Cr &gt; 1.5 time upper limit normal , white blood cell count &lt; 4.0×109 platelet &lt; 100×109 , hemoglobin &lt; 100 g/L , blood glucose &gt; 1.5 time upper limit normal ; 6 . In screening , systolic blood pressure ≥160 mmHg &lt; 90 mmHg , diastolic blood pressure ≥100 mmHg &lt; 60 mmHg ; 7 . Unstable severe cardiac , pulmonary , hepatic , renal hematopoietic disease ( include unstable angina , uncontrolled asthma , active gastric bleeding cancer ) , 10 min rest , rest heart rate &lt; 60 bpm ; 8 . Visual hearing disorder , prevent completion neuropsychological test scale evaluation ; 9 . In screening , MRI examination show significant focal lesion , subject ≤ 70 age , Fazekas scale white matter lesion &gt; grade 1 , subject &gt; 70 age , scale &gt; grade 2 , 2 lacunar infarction lesion diameter &gt; 2 cm , lacunar infarction lesion vital site , thalamus , hippocampus , entorhinal cortex , paraolfactory cortex , cortex subcortical gray matter nucleus ; 10 . Alcohol abuse drug abuse ; 11 . Patients psychosis , include severe depression ; 12 . Patients use drug Alzheimer 's disease stop ; 13 . Use heparin , Propylene Glycol Mannurate Sulfate Alginric Sodium Diester within 3 week prior screen ; 14 . Inability take trial drug accord prescription , previous noncompliance prescription possibility noncompliance study treatment trial ; 15 . Investigators consider subject complete study ; 16 . Subjects phase II trial study drug ; 17 . Subjects investigator participate study direct relative , staff Quintiles ( Shanghai ) Shanghai Greenvalley Pharmaceutical Co. , Ltd. direct relative .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>